Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001193125-23-286398
Filing Date
2023-11-30
Accepted
2023-11-30 17:18:10
Documents
5

Document Format Files

Seq Description Document Type Size
1 424B3 d855916d424b3.htm 424B3 198418
2 GRAPHIC g855916dsp14a.jpg GRAPHIC 3807
3 GRAPHIC g855916dsp14b.jpg GRAPHIC 6033
4 GRAPHIC g855916g1128084939980.jpg GRAPHIC 3643
5 GRAPHIC g855916g1201013539729.jpg GRAPHIC 3642
  Complete submission text file 0001193125-23-286398.txt   223738
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-273769 | Film No.: 231456653
SIC: 2834 Pharmaceutical Preparations